Manejeh Yaqub
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Manejeh Yaqub has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra J. Lansky
Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA
3 shared publications - Gregg Whitney Stone
Icahn School of Medicine at Mount Sinai , New York, NY
3 shared publications - Krishnankutty Sudhir
Abbott Vascular, Santa Clara, USA
3 shared publications Poornima Sood
Abbott Vascular, Santa Clara, California
3 shared publicationsJames B. Hermiller
St. Vincent's Heart Center of Indiana, Indianapolis, Indiana
2 shared publicationsRobert J. Applegate
Wake Forest University Health Sciences, Winston-Salem, North Carolina
2 shared publications
Latest Publications
- Open Access
- 1 August 2024
- Published by Springer Nature in Ophthalmology and Therapy
- Vol. 13 (9) , 2303-2329
Systematic Literature Reviews Comparing the Long-Term Safety Outcomes for the Port Delivery System with Ranibizumab (PDS) Versus Other Ocular Implants
Objectives To determine whether the types and rates of post-surgical complications associated with the Port Delivery System with ranibizumab (PDS) are comparable with those reported for other ocular implants that cross the sclera. Methods Systematic literature reviews were conducted to determine the long-term (≥ 18-month) safety of ocular implants that cross the sclera in clinical trials and real-world studies. Complication types and rates were compared with those reported for the PDS in phase III clinical trials (Archway, Pagoda, and Pavilion). Results Sixteen clinical trials (24 publications) and 43 real-world studies were identified reporting 30 complications in eyes with 15 implant types and 8 ocular diseases. Implants were associated with an acceptable, well-characterized safety profile, with most complications resolving spontaneously or with treatment. Device-related complications were reported in 0.7% (0.0–5.0%) of study eyes in clinical trials and 1.3% (0.0–14.5%) of eyes in real-world studies. Rates of conjunctival complications were 2.1% (0.0–22.8%) and 2.2% (0.9–4.6%), respectively. The overall types and rates of adverse events of special interest reported for the PDS in phase III trials (cataract, conjunctival bleb, vitreous hemorrhage, conjunctival erosion, conjunctival retraction, endophthalmitis, implant dislocation, retinal detachment, and hyphema) were within the ranges reported for other ocular implants. Conclusions The rates of complications reported in phase III clinical trials for the PDS were within the ranges reported for other ocular implants that cross the sclera. This suggests that the long-term safety of the PDS is consistent with other ocular devices established in ophthalmology clinical practice. Trial Registration PROSPERO international prospective register of systematic reviews: CRD5202234129, CRD42022343129.
- 1 August 2024
- Published by Springer Nature in Ophthalmology and Therapy
- Vol. 13 (9) , 2303-2329
Open AccessSystematic Literature Reviews Comparing the Long-Term Safety Outcomes for the Port Delivery System with Ranibizumab (PDS) Versus Other Ocular Implants
Objectives To determine whether the types and rates of post-surgical complications associated with the Port Delivery System with ranibizumab (PDS) are comparable with those reported for other ocular implants that cross the sclera. Methods Systematic literature reviews were conducted to determine the long-term (≥ 18-month) safety of ocular implants that cross the sclera in clinical trials and real-world studies. Complication types and rates were compared with those reported for the PDS in phase III clinical trials (Archway, Pagoda, and Pavilion). Results Sixteen clinical trials (24 publications) and 43 real-world studies were identified reporting 30 complications in eyes with 15 implant types and 8 ocular diseases. Implants were associated with an acceptable, well-characterized safety profile, with most complications resolving spontaneously or with treatment. Device-related complications were reported in 0.7% (0.0–5.0%) of study eyes in clinical trials and 1.3% (0.0–14.5%) of eyes in real-world studies. Rates of conjunctival complications were 2.1% (0.0–22.8%) and 2.2% (0.9–4.6%), respectively. The overall types and rates of adverse events of special interest reported for the PDS in phase III trials (cataract, conjunctival bleb, vitreous hemorrhage, conjunctival erosion, conjunctival retraction, endophthalmitis, implant dislocation, retinal detachment, and hyphema) were within the ranges reported for other ocular implants. Conclusions The rates of complications reported in phase III clinical trials for the PDS were within the ranges reported for other ocular implants that cross the sclera. This suggests that the long-term safety of the PDS is consistent with other ocular devices established in ophthalmology clinical practice. Trial Registration PROSPERO international prospective register of systematic reviews: CRD5202234129, CRD42022343129.
- 1 July 2011
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 7 (3) , 307-313
Clinical and angiographic outcomes of elderly patients treated with everolimus-eluting versus paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
- 1 July 2011
- Published by Europa Digital & Publishing in EuroIntervention
- Vol. 7 (3) , 307-313
Clinical and angiographic outcomes of elderly patients treated with everolimus-eluting versus paclitaxel-eluting stents: three-year results from the SPIRIT III randomised trial
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
- 1 March 2011
- Published by Elsevier in The American Journal of Cardiology
- Vol. 107 (6) , 841-848
Three-Year Results of Safety and Efficacy of the Everolimus-Eluting Coronary Stent in Women (from the SPIRIT III Randomized Clinical Trial)
- 1 March 2011
- Published by Elsevier in The American Journal of Cardiology
- Vol. 107 (6) , 841-848
Three-Year Results of Safety and Efficacy of the Everolimus-Eluting Coronary Stent in Women (from the SPIRIT III Randomized Clinical Trial)